RESULTS	There was a higher proportion of patients with treatment-resistant disease ( < 25 % reduction of serum AP ) in the etidronate group ( 51.9 % ) than in the tiludronate 3-month group ( 17.9 % ) or the tiludronate 6-month group ( 19.5 % ) ( P < 0.0001 ) .\